Routine in vitro screening of a new synthetic series of 3,5-substituted 2-methylisoxazolidines revealed that three imidazole analogs and, to a lesser extent, a triazole analog exerted rather potent antifungal activity against three systemic and four dermatophytic classes of fungi. When tested in vivo for ability to eradicate Candida vaginitis in the rat, the triazole derivative, PR 988-399, was effective after oral administration. In this in vivo test for efficacy, reduced but did not eradicate the infection, while PR 967-248 was inactive. PR 988-399 was, moreover, 4-to 13-fold less potent than the three imidazoles in inhibiting testosterone synthesis in isolated rat Leydig cells. After oral or intravenous administration, PR 988-399 and PR 969-566 elicited the fewest cardiovascular and behavioral side effects in conscious dogs. The rat safety study consisted of oral dosing followed by evaluation of the exploratory motor activity of the naive animals in a novel environment. Motor activity was suppressed least by PR 988-399 and most by PR 969-566. In a battery of mouse behavioral-neuromuscular-drug interaction tests, PR 988-399 and PR 969-566 produced the fewest central-behavioral-neuromuscular signs. These efficacy-safety evaluations were performed with ketoconazole as a positive reference standard. The sequence of drug testing with respect to efficacy-safety considerations appears to be a suitable approach for early detection of orally active antifungal agents such as PR 988-399 for more advanced development.
The incidence of systemic fungal infections, such as those caused by Candida albicans, has been on the rise. The most likely explanation is the increasing number of immunocompromised patients (13, 14, 20, 30) as well as, for example, a recently reported syndrome of C. albicans septicemia in heroin addicts (13) . Major problems with earlier antifungal therapies were the requirement for parenteral administration and untoward effects. Not until the advent of the azole derivative ketoconazole in the 1970s were orally effective agents available (5, 13, 14, 19) . Ketoconazole and other developed azoles were not without their respective liabilities (13, 14, 32, 34, 36) . Therefore, a continuing need exists to develop newer agents which possess the following properties: novel structures, fungicidal activity, highly specific or broad-spectrum profiles of antifungal activity, orally active, safer, better tissue distribution (especially penetrability in the cerebrospinal fluid, body fluids, and urinary tract), longer duration of action, less propensity to induce liver enzymes, limited or no action on steroidogenesis and associated endocrine organs, and novel sites of action (14, 30 ; also see preceding reviews [5, 13, 14, 19, 32, 36] for discussion). New azole derivatives and triazole antifungal agents have been synthesized, resulting in advanced clinical trials for the promising agents itraconazole and fluconazole (13, 32) .
We have developed four new synthetic series of 3,5-substituted 2-methylisoxazolidines which proved active when screened for antifungal efficacy under in vitro conditions (for syntheses, see references 4, 10, 22, and 23). However, since in vitro activity does not consistently correlate with in vivo efficacy (notably with testing for flucon-azole) (32), we developed a rational approach for early identification of promising orally active compounds based on acute in vitro-in vivo efficacy-safety profiles. For in vivo efficacy, the rat model of Candida vaginitis was employed (1) . Safety considerations were based on endocrine (inhibition of testosterone synthesis in rat Leydig cells), central nervous system (dog, rat, and mouse models), and cardiovascular (dog) paradigms. In this manner, we report findings for the four most promising compounds from the separate chemical series, namely, PR 988-399, PR 969-566, PR 967-248, and PR 967-234 (see structures in Fig. 1 ). Ketoconazole was used as a positive reference standard. The testing sequence identified PR 988-399 as the compound with the highest potential for further extensive development.
MATERIALS AND METHODS
Compounds. The chemical names of the antifungal compounds used in the present investigation are listed below. The syntheses have been recently published (4, 10, 22, 23) . in vitro at which fungal growth was arrested (MIC) was determined by using a solid agar technique as described by McGinnis (18) . All the fungi were grown on antibiotic-testing medium no. 3 (Difco Laboratories, Detroit, Mich.). All tests were performed in triplicate, and incubations were conducted at 300C. The test compounds were initially dissolved in 100% dimethyl sulfoxide, whereas ketoconazole was dissolved in 0.2 N HCI. Portions (3 For the mold species, the technique was performed essentially as just described. If the mold was not a good sporeformer, the mycelia were carefully scraped from the surface of the plate, ground up with a tissue grinder, and adjusted to an optical density of 0.5 to 0.6 at 450 nm. After solidification, all test plates were inoculated with 0.05 ml of the fungal suspension and left undisturbed until the inoculum had been absorbed into the SDA. The plates were then incubated until visible growth appeared in the drug-free control.
The MICs of individual antifungal compounds against specific fungal strains were assigned rank orders of potency according to the following criteria: rank 1 = >70,ug/ml, rank 2 = 20,ug/ml, rank 3 = 7,ug/ml, rank 4 = 2 pug/ml, rank 5 = 0.7 ,ug/ml, rank 6 = 0.2 ,uglml, and rank 7 = <0.2 ,ug/ml. These MIC ranks were compared among the different antifungal compounds by Friedman's test as described in the BMDP statistical manual (2), using the BMDP-3S program (nonparametric statistics).
In vivo rat vaginal candidiasis. The in vivo rat candidiasis studies utilized a modification (1) of the method described by Polak (27) . Ovariectomized female Sprague-Dawley rats, 150 to 175 g (Harlan Laboratories, Inc., Indianapolis, Ind.), were maintained on a diet of laboratory rat chow and water ad libitum. A 0.1-ml subcutaneous injection of estradiol valerate (0.5 mg of Delestrogen; E. R. Squibb & Sons, Princeton, N.J.) was given 4 days prior to infection to induce pseudoestrus. Animals were maintained in pseudoestrus by weekly injections of 0.5 mg of estradiol valerate.
The appropriate clinical C. albicans isolate was initially cultured on SDA. Isolated colonies were picked from the surface of the plate, placed in 50 ml of Sabouraud dextrose broth (Difco), and allowed to grow for 22 h on a clinical rotator at room temperature. After 22 h of incubation, the broth appeared to be turbid, indicating active microbial growth. Aliquots (1 ml) of this stock broth culture were frozen at -20°C until further use.
To prepare sufficient numbers of organisms to induce vaginal candidiasis, we placed a 1-ml aliquot of the specific clinical isolate of C. albicans in a 50-ml flask containing 10 ml of 1% Phytone-peptone broth (BBL Microbiology Systems, Cockeysville, Md.) and 1% glucose. The flasks were incubated on a clinical rotator for 36 h at room temperature. At the end of the incubation period, the contents were centrifuged at room temperature at 500 x g for 10 min. The supernatant was removed, and the pellet was suspended in RPMI 1640 medium containing 100 U of penicillin G per ml and 100 ,ug of streptomycin per ml, all purchased from Sigma Chemical Co. (St. Louis, Mo.). The suspended yeasts were enumerated by hemacytometer counting and diluted to a concentration of 108 organisms per ml.
Four days after the first estradiol injection, the animals were tranquilized by an intraperitoneal injection of 10 mg of ketamine hydrochloride (Vetalar; Parke-Davis, Morris Plains, N.J.). Each animal was suspended head down, and a dry cotton swab was inserted into the vagina to dilate it.
Following this dilation, 0.1 ml of the Candida inoculum (107 CFU) was inserted into the vagina with a 1-ml tuberculin syringe with a 1-cm length of butterfly tubing attached.
To sample repetitively each vagina for recoverable Candida organisms, we first anesthetized the animal with ketamine as described above. Then a sterile swab moistened with sterile phosphate-buffered saline was inserted into the vagina and twisted several times before removal. The swab was then swirled in 0.3 ml of sterile phosphate-buffered saline. The resultant suspension of vaginal lavage fluid was then logarithmically diluted, and a 0.1-ml sample was placed on an SDA plate which was prepared 72 h earlier and dried at room temperature. The lavage fluid was spread evenly To evaluate fungal virulence, persistence, and reproducibility across different studies, as well as to compare antifungal activity between antifungal compounds, a withinsubject, repeated-measures analysis of variance (ANOVA) was performed. When the slope of the time-response curves for two given drug treatments were not different (treatmentday interaction was not significant), either Newman-Keuls or pairwise ANOVA tests were used to compare relative effects of specific drug and dose treatments across days. When the slopes of the time-response curves for any two drug treatments were different (significant interactions among drug or doses across days), Newman-Keuls tests were performed for each day individually with no attempt to analyze drug effects over time.
In vitro inhibition of testosterone synthesis in rat Leydig cell suspensions. Leydig cells were isolated and prepared from rat testes (Sprague-Dawley rats, 325 to 350 g) by a modification of the methods previously described (21) . Testes were trimmed of excess fat and decapsulated. The testes were then added to 10 ml of medium 199 containing 2 mg of bovine serum albumin per ml and 0.25 mg of collagenase (type 1) per ml in 50-ml conical polypropylene tubes. The tubes were gassed with a 5% C02-95% 02 mixture, tightly capped, placed in a Dubnoff incubator, and shaken at 100 cycles per min for 20 min at 37°C. The tubes were then filled to the 40-ml mark with medium 199 containing 2% bovine serum albumin, inverted gently to separate Leydig cells from the tubular mass, and allowed to settle for 10 min. The supernatants containing the Leydig cells were decanted into clean 50-ml tubes, and the original tubes with the tubular mass were washed with 50 ml of the medium 199-bovine serum albumin solution. After settling for 10 min, the supernatants were combined and centrifuged for 15 min at 100 x g. The pellets were washed twice and suspended in approximately 25 ml of medium 199 in 40-ml tubes.
The tubes containing the Leydig cell suspension were incubated for 30 min at 25°C with selected log dose concentrations of the respective antifungal agents which were dissolved in 0.1 N HCI (100 ,ul/2 ml of cell suspension). Since pilot studies showed that basal synthesis of testosterone was too low to examine possible inhibition, testosterone synthesis was stimulated with human chorionic gonadotropin (Sigma). The human chorionic gonadotropin was added at 10 IU/2 ml to all tubes except the nonstimulated controls, and the cell suspensions were incubated for 3 h at 37°C in an atmosphere of 5% C02-95% 02. Following the incubation period, testosterone was extracted with dimethyl ether (5 ml/ 2-ml sample) and evaporated to dryness. The samples were then dissolved in 100 ,ul of artificial plasma (designated as A calibrator) obtained from the Diagnostic Products RIA Testosterone Kit.
The levels of testosterone were analyzed from each pair of duplicate samples with a standard radioimmunoassay kit (Diagnostic Products). The percentage of inhibition of testosterone synthesis was determined by comparing the level of testosterone in each test sample with that of the corresponding control.
The concentration of antifungal agent required to inhibit in vitro testosterone synthesis by 50% (50% inhibitory concentration) was obtained by combining the data from five separate experiments, each with at least seven concentrations (0.5 M increments from 10-4 to 10' M, obtained by pretesting the drugs at log increments) of drugs, and by using the ALL-FIT analysis, an iterative curve-fitting program for families of dose-response curves based on a four-parameter logistic equation (11) . Best fit was achieved when curves were constrained such that all a parameters were shared (i.e., drug responses at zero dose) and all d parameters were equal to 100% (i.e., 100% inhibition at infinite dose).
Mouse Neural impairment tests. The neural impairment screens were conducted in three separate but neurologically related tests: (i) the inverted screen, a measure of vestibularneuromuscular coordination (7), (ii) the inclined screen, principally a measure of neuromuscular coordination (9) , and (iii) the wire maneuver, which assesses limb reflex involving forelimb and hindlimb grip strength (9 The drug doses of 1 and 3 mg/kg and the corresponding vehicle treatments were administered as bolus injections, and each dose was followed by a 15-min observation period.
The 10-and 30-mg/kg doses and corresponding vehicle treatments were infused at a rate of 2 mg/ml per min. A 30-min observation period followed the 10-mg/kg infusion, and 60 min of observation followed the highest dose. Statistical evaluation of the results compared responses obtained between treatment groups for each route of administration. Thus, groups treated with PR 988-399FB or its vehicle were compared for differences by an ANOVA with a repeated-measures design (BMDP-2V) (2) . If the response patterns were significantly different, the Newman-Keuls procedure (RANGE test) was applied to compare the two groups in terms of change from pretreatment level at each posttreatment time point.
RESULTS
In vitro antifungal activity. Table 1 contains a detailed summary of the range of the MICs (expressed as micrograms per milliliter) at which fungal growth was arrested by the reference agent ketoconazole and the four newly synthesized antifungal agents. Using Friedman's test, we compared the rank order of potencies of the MICs for the five antifungal compounds against three strains of systemic fungi and four strains of dermatophytic fungi. The rank order for inhibition of fungal growth was not significant among the four most potent compounds, namely, ketoconazole, PR 0.0083) when compared against the other four compounds (statistical details are presented in Table 1 , footnote b).
In the subsequent section, the test compounds were evaluated in vivo against two strains of C. albicans causing rat candidial vaginitis, namely, SC9172 and FM391. The compounds were likewise tested for in vitro efficacy against these two strains. The MICs and the rank orders of potency (in parentheses) for the in vitro tests were as follows: (i) strain SC9172, ketoconazole = <0.2 ,ug/ml (7), PR 988-399 = 0.2 to 0.7 ,ug/ml (6), PR 969-566 = 0.7 to 2 ,ug/ml (5), PR 967-248 = 0.7 to 2 ,ug/ml (5), PR 967-234 = 2 to 7 ,ug/ml (4); and (ii) strain FM391, ketoconazole = 2 to 7 ,ug/ml (4), PR 988-399 = 7 to 20 ,ug/ml (3), PR 969-566 = 0.7 to 2 ,ug/ml (5), PR 967-248 = 0.7 to 2 ,ug/ml (5), PR 967-234 = 2 to 7 ,ug/ml (4). The Friedman's test statistic equaled 2.00 (P = 0.1573), indicating no significant difference in rank order of potency among the compounds for the two strains.
In vivo rat vaginal candidiasis. The in vivo rat model of vaginal candidiasis was used to determine the efficacy of the compounds. Our criterion, prior to more extensive development, for examining and screening promising compounds was a requirement that the test drug be as effective at 20 mg/ kg orally as the reference agent, ketoconazole. Ovariectomized rats (eight per group) were injected with 0.5 mg of estradiol 4 days prior to vaginal infection with one of two strains of C. albicans. At 24 h postinfection, animals were administered the appropriate antifungal agent or vehicle (20 mg/kg twice a day orally). The vaginal tracts were sampled daily to determine the number of recoverable viable organisms. The virulence and persistence of strain SC9172 was comparable over days of infection to strain FM391 (a 2 x 6 ANOVA test revealed no significant strain differences across 8 days of infection) (Fig. 2) .
In (Table 2) .
Behavioral signs in mice after oral dosing. (Table   3) .
A perusal of the summary of findings in Table 3 revealed that with respect to oral dosing, the subjective rank order of safety for the five antifungal agents in mice (fewest to most severe symptoms) was PR 969-566 (1), PR 988-399 (2), PR 967-234 (3), ketoconazole (4), and PR 967-248 (5).
Neural impairment. Initial dosing was 400 mg/kg (oral), and doses were scaled upward or downward depending on responses observed for a particular drug under a specific neural impairment-testing situation. It became readily apparent that in the inverted screen test, failures of mice to negotiate the task did not follow dose-response relationships even if acute doses as high as 1,000 to 1,200 mg/kg were attempted. The exception was PR 967-234, for which doses higher than 800 mg/kg resulted in death. The observed lack of dose-response relationships was also evident for the inclined screen and wire maneuver tasks. The exception again was PR 967-234 and also PR 967-248 (wire maneuver only), for which toxic doses that inhibited the response by 50% (TD50s) were obtained. Respective TD50s calculated by the AEL-50 program were as follows: (i) PR 967-234, inclined screen, TD50 = 230 mg/kg (321 to 166); slope = 4.7 + 1.2; (ii) PR 967-234, wire maneuver, TD50 = 247 mg/kg (343 to 179), slope = 4.9 ± 1.2; and (iii) PR 967-248, wire maneuver, TD50 = 627 mg/kg (1, 349 to 459), slope = 3.4 ± 1.1. The values in parentheses are 95% confidence limits, and the slope is the mean ± the standard error (SE).
As described in the Materials and Methods, chi-square comparisons were made between compounds and across the three neurologically related neural impairment tests by measuring responses obtained at 600 and 900 mg/kg. The first relationship compared all five compounds with controls, and a significant degree of neural impairment was observed across the three tests at the 900-mg/kg dose (see Table 4 for chi-square analyses). At the 600-mg/kg dose, compounds PR 988-399 and PR 969-566 did not produce significant impairment, whereas PR 967-234, as expected from the TD50 analyses, produced the worst impairment, while ketoconazole and PR 967-248 followed in rank order of significance (Table 4) .
The second statistical evaluation for neural impairment compared the four Fisons compounds with the reference Los 900 PALMER ET AL. (ii) Phenyl-p-benzoquinone-induced writhing. At the highest oral doses tested, PR 967-248 (300 mg/kg) protected 20% of mice from phenyl-p-benzoquinone-induced writhing. Similarly, PR 967-234 afforded a 40% protection at 400 mg/kg. No other agents were effective in this test.
(iii) Oxotremorine-induced tremor and salivation. The antifungal compounds when administered at large oral doses were all inactive in the oxotremorine test.
(iv) Tremors induced by LON 954. All antifungal compounds except PR 967-234 were unable to protect mice against tremors elicited by LON 954. The oral 50% effective dose was 154 mg/kg (95% confidence limits, 107 to 234) with a slope ± SE of 2.22 ± 0.5 (data obtained by the AEL-50 program).
(v) Antihypoxia screen. The initial test dose to determine whether the antifungal compounds would extend survival time when mice were exposed to a hypoxic environment was 400 mg/kg orally, except for PR 967-248 (300 mg/kg). The survival time (mean ± SE) of normal mice exposed to the hypoxic environment was 2.3 + 0.2 min (n = 25). The percent extension of survival times over respective control groups for the initial high oral doses of antifungal agents were (mean percent ± SE): ketoconazole, 71 + 12 (P = 0.06, Student's pooled t test); PR 988-399, 60 ± 5 (P = 0.001); PR 969-566, 48 + 4 (P = 0.001); PR 967-248, 57 + 8 (P = 0.001); and PR 967-234, 20 + 5 (not significant). The large SE of the mean for ketoconazole with respect to its control group accounts for the lack of significance. The study was then redesigned to obtain direct comparisons of antihypoxic activity with two doses (50 and 100 mg/kg) and 10 mice per dose. The 50-mg/kg dose did not significantly influence survival. However, the 100-mg/kg dose was effective, with ketoconazole extending survival time by 82% (P = 0.001) and PR 967 248 extending survival time by 72% (P = 0.001). The mean survival time for controls in this experiment was 2.2 ± 0.09 min (n = 30).
Acute exploratory motor activity in naive rats. In the three separate studies utilizing the Optovarimex system to monitor acute exploratory motor activity in naive rats, the total distance traveled by controls was consistently greater upon the initial exposure (1-h testing time) of the animals to the apparatus. At the 6-and 24-h testing times, the total motor activity was from 10 to 35% less than that at 1 h. During dose-ranging studies, both ketoconazole and PR 988-399 were found to be ineffective at doses of 7, 20, 40, 80, and 160 mg/kg (orally). At higher oral doses (320 and 640 mg/kg) of ketoconazole and PR 988-399, there were significant decrements in distance traveled over the time course of the experiment. The BMDP-2V analysis of the ketoconazole and PR 988-399 findings showed significant effects owing to treatment, interval, and treatment-by-interval interaction. 
DISCUSSION
Since the incidence of C. albicans infections is rising owing to better diagnosis, appearance of drug-resistant organisms, and the susceptibility of the increasing numbers of immunocompromised patients (13, 14, 19, 20, 30, 36) , our therapeutic goal was to develop an effective and safe oral treatment for humans. A candidate compound should be of equal or greater potency and safety than the leading marketed compound, ketoconazole (5, 14, 26, 35) . Critical factors in the rational development of new orally active antifungal agents are standardized, quantitative, and coordinated approaches involving chemical discovery and acute preclinical efficacy-safety evaluations of promising novel antifungal candidates compared with positive reference compounds. One of the problems faced by us was the paucity of pharmacological data available for such a study. Most reports would describe in vitro antifungal efficacy, but the safety as well as reliable in vivo tests for efficacy were usually lacking. One report (24) described ketoconazole, but the array of testing procedures was too extensive for simultaneous evaluation of several active compounds. From the four chemical series described here (4, 10, 22, 33) , active compounds emerged from in vitro testing for antifungal activity. Thus, the testing sequence next examined all active compounds for acute safety utilizing the rapid tests for behavioral signs (6, 16) and neural impairment (7, 9) (15, 31, 32) has also shown weaker in vitro antifungal activity for triazole compounds including new drugs in advanced clinical trials, namely, itraconazole and fluconazole. Notably, the triazole analog of ketoconazole was also less potent. Triazoles usually have limited solubility (15) . The findings with ketoconazole support earlier work describing its ability to inhibit in vitro fungal growth under a variety of testing conditions (15, 26, 35) .
The initial safety screens in mice indicated that with regard to production of behavioral signs (6, 16) , PR 969-566 followed by PR 988-399 were the safest drugs, while PR 967-248 was the least safe. However, high oral doses of 200 to 400 mg/kg were required to produce symptoms with any of the compounds. Both PR 969-566 and PR 988-399 elicited the lowest incidences of neural impairment (7, 9) . In these tests, PR 967-234 was the most toxic compound. Acute doses as high as 1,000 to 1,200 mg/kg rarely caused mortality, except for PR 967-234. The hypothermia produced by ketoconazole and its relative ineffectiveness on motor performance confirm earlier work (24) .
Limited oral in vivo efficacy with respect to anticandidal activity was observed for PR 969-566 and PR 967-234, while PR 988-399 and ketoconazole eradicated the infections caused by two equally virulent Candida strains, and PR 967-248 was inactive. Moreover, PR 988-399 demonstrated a 2-day lag period for onset of antifungal activity, but eradication by day 8 was similar to that of the reference agent. The data for ketoconazole are in agreement with other investigations which reveal efficacy against a variety of candidal infections involving laboratory animals and humans (5, 15, 26, 31, 33, 35) .
Active imidazoles exert antifungal activity by increasing membrane permeability by interfering with ergosterol synthesis, the main sterol in fungal membranes. In mammals, acute administration of ketoconazole prevents formation of testosterone and higher sustained doses suppress cortisol as well. The site of action is a selective inhibition of C17_20 lyase enzyme involved in the initial steps in the synthesis of the two steroids (14, 34, 36 (32, 36) . In the present study and earlier work, only the highest doses of ketoconazole exerted central analgesic (24) , anticonvulsant (24) , or antihypoxic properties. The latter action could be a result of hypothermia; however, an attempt was made to control for this problem (3) . Of 
